Clinical Trial Update: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oxaliplatin, capecitabine (Xeloda), and cetuximab as first-line therapy for metastatic or unresectable gastric or gastroesopha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• OXALIPLATIN (Oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: University of Southern California | Conditions: Gastric Cancer, Esophageal Cancer | Phase 2 | Status: UNKNOWN